Wire · founder news, decoded · opportunities
FDA Approves Enlicitide, an Oral PCSK9 Inhibitor, for LDL-Lowering | tctmd.com
The FDA has approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor for LDL-lowering, as a once-daily alternative to existing injectable options from Amgen, Novartis, and Sanofi/Regeneron. The approval is based on phase III trial data showing 55–59% LDL reduction versus placebo, with comparable safety to injections.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you sell support tools, patient adherence software, or cost-management platforms into the PCSK9 market, your moat just shifted: oral pills scale faster than injections and will soon attract price-conscious payers who've held these drugs as premium-only. Merck's real win isn't the drug—it's the 14,500-patient outcomes trial that will either bury the other four PCSK9s or force them into combination therapy, turning you into a downstream dependency for whichever one survives.
Read the full story at tctmd.com →
Topics: Digital Health · pcsk9-inhibitors · oral-formulation · cholesterol-treatment · fda-approval · competitive-displacement